FDA Grants Fast Track Status to IMM-1-104 for Pancreatic Cancer

IMM-1-104 received FDA fast track designation for use in patients with pancreatic ductal adenocarcinoma who have progressed on 1 line of treatment.

Related Keywords

California ,United States ,Vincent Chung ,Ben Zeskind ,Treatment Group ,Department Of Medical Oncology ,Immuneering Corporation ,Therapeutics Research At City Of Hope ,Tumor Growth Assay ,Medical Oncology ,Therapeutics Research ,Gastrointestinal Cancer ,News ,Fda ,Pancreatic Cancer ,Imm 1 104 ,